MOTCO’s Intellia Therapeutics NTLA Stock Holding History

MOTCO’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-100	Closed	-$2.06K	–	554
2024 Q3	$2.06K	Hold	100	–	–	﹤0.01%	553
2024 Q2	$2.24K	Buy	+100	New	+$2.38K	﹤0.01%	655

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MOTCO's NTLA Position: Q4 2024 in Review

MOTCO sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 100 shares — an estimated $2.06K sold.

MOTCO first reported a position in NTLA in Q2 2024 and held it in 2 quarters. The position peaked at $2.24K in Q2 2024. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

MOTCO reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
MOTCO sold 100 Intellia Therapeutics shares in Q4 2024, an estimated $2.06K.
MOTCO first reported a position in Intellia Therapeutics in Q2 2024 and held it in 2 quarters.
MOTCO's Intellia Therapeutics position peaked at $2.24K in Q2 2024.
293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on MOTCO's 13F filing for Q4 2024, filed 5 Feb 2025.